HomepageLSI • FRA
add
CK Life Sciences Intl (Holdings) Inc
Vorige slotkoers
€ 0,092
Dag-range
€ 0,092 - € 0,092
Jaar-range
€ 0,047 - € 0,11
Beurswaarde
8,27Â mld. HKD
Gem. volume
679,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
HKG
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (HKD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,30Â mld. | -1,14% |
Bedrijfskosten | 413,65Â mln. | 27,86% |
Netto inkomsten | -75,42Â mln. | -15.168,63% |
Netto winstmarge | -5,79 | -14.575,00% |
Winst per aandeel | — | — |
EBITDA | 4,66Â mln. | -95,31% |
Effectief belastingtarief | -11,85% | — |
Balans
Totale activa
Totale passiva
| (HKD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 797,84Â mln. | 41,94% |
Totale activa | 11,29Â mld. | 3,66% |
Totale passiva | 7,63Â mld. | 11,04% |
Totaal aandelenvermogen | 3,65 mld. | — |
Uitstaande aandelen | 9,61 mld. | — |
Koers-boekwaardeverhouding | 0,24 | — |
Rendement op activa | -0,37% | — |
Rendement op kapitaal | -0,41% | — |
Kasstroom
Nettomutatie in liquide middelen
| (HKD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -75,42Â mln. | -15.168,63% |
Operationele kasstroom | -3,03Â mln. | -104,17% |
Kasstroom uit beleggingen | 9,20Â mln. | 119,22% |
Kasstroom uit financiering | 103,54Â mln. | 233,22% |
Nettomutatie in liquide middelen | 118,57Â mln. | 305,99% |
Vrije kasstroom | -33,81Â mln. | -290,23% |
Over
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Victor Li Tzar-kuoi, the eldest son of Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
Opgericht
2000
Website
Werknemers
1.935
